18.207.132.226
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Retina

Ranibizumab biosimilar candidate meets efficacy, safety outcomes for treatment of nAMD

Posted on December 15, 2020

A proposed biosimilar to reference ranibizumab met the primary outcome of similarity to ranibizumab for efficacy and safety in the treatment of patients with treatment-naive nAMD, according to a poster presented at AAO 2020 Virtual.

A total of 429 patients were randomized to receive the biosimilar FYB201 (n = 215) or ranibizumab (n = 214) every 4 weeks for 48 weeks. The mean change from baseline in best corrected visual acuity (BCVA) at 8 weeks was 5.2 and +6.0 EDTRS letters for patients treated with FYB201 and ranibizumab, respectively. At 48 weeks, similar efficacy was maintained with a mean change of +7.9 and +8.5 EDTRS letters, respectively.

Secondary efficacy endpoints, safety, immunogenicity, and pharmacokinetics were similar between the groups.

Reference
Holz FG, et al. COLUMBUS-AMD: Efficacy and Safety of FYB201, a Proposed Biosimilar to Ranibizumab, in nAMD. Presented at: AAO 2020 Virtual.

-Advertisement-
Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-